Biopharma news, November 19, 2026
5 stories
In this digest: Approval 3 · Pivotal readout 2
Top stories
FDA Approves Venglustat
Sanofi announced FDA approval of venglustat for neurological symptoms of type 3 Gaucher disease in adults and children weighing at least 15 kg, describing it as the first US treatment for those symptoms. In the 43-patient phase 3 LEAP2MONO trial, venglustat showed a significant neurological benefit over imiglucerase; platelet count did not meet the noninferiority criterion. Venglustat is under review in the EU, and Sanofi plans further submissions in other regions in 2026.
- Drugvenglustat
- TargetUDP-glucose ceramide glucosyltransferase
- TargetProtein N-terminal methyltransferase 1
- TrialNCT05222906
Source types: Press release · News article
Toludesvenlafaxine Wins Anxiety Approval
Luye Pharma's toludesvenlafaxine was approved in China for the treatment of generalized anxiety disorder. The approval appeared on the National Medical Products Administration website on November 19, under application numbers CXHS2600006 and CXHS2600007.
Read more about Toludesvenlafaxine Wins Anxiety Approval
The headline describes the approval as a first in nearly 20 years, without specifying the scope of that claim in the provided text.
- Drugtoludesvenlafaxine
- TargetDopamine plasma membrane transport protein
- TargetNorepinephrine transporter
- TrialNCT05970510
Source types: News article
Solepinib Wins Dual China Approval
China's NMPA approved HUTCHMED's solepinib for two adult indications: previously treated primary chronic immune thrombocytopenia and warm antibody autoimmune hemolytic anemia.
Read more about Solepinib Wins Dual China Approval
The oral spleen tyrosine kinase inhibitor is reported to be the first domestically developed Syk inhibitor approved in China. The resubmitted immune thrombocytopenia application was accepted in February 2026, and the warm antibody autoimmune hemolytic anemia application was accepted in April 2026.
Source types: News article
News in brief
Xanamem Misses Primary Endpoint
Read more about Xanamem Misses Primary Endpoint
The 247-person XanaMIA trial missed its primary endpoint: Xanamem's 0.10-point CDR-SB advantage over placebo at week 36 was not statistically significant (p=0.65). Among participants older than 75, 40% receiving Xanamem had no CDR-SB progression versus 22% on placebo (p=0.02); the subgroup's mean CDR-SB difference was not statistically significant (p=0.22). No serious adverse events were attributed to Xanamem. Actinogen plans further analysis and discussions with potential partners and the FDA.
Source types: Press release
Regeneron Announces ASH Data
Read more about Regeneron Announces ASH Data
Regeneron plans to present hematology research across 14 abstracts at ASH 2026 in New Orleans, including potentially pivotal Ordspono results in relapsed or refractory marginal zone lymphoma. Lynozyfic presentations will cover updated systemic light chain amyloidosis data and analyses in multiple myeloma; other presentations address investigational therapies for paroxysmal nocturnal hemoglobinuria and blood disorders. The release announces presentations but provides no numerical efficacy or safety results. The highlighted uses of Ordspono and Lynozyfic in marginal zone lymphoma and amyloidosis, respectively, remain investigational.
Source types: Press release
Sources are available to Gosset users. Log in to see them.
All digests
- November 18, 2026 5 stories
- November 17, 2026 5 stories
- November 16, 2026 3 stories
- November 15, 2026 4 stories
- November 14, 2026 5 stories
- November 13, 2026 5 stories
- November 12, 2026 10 stories
- November 11, 2026 10 stories
- November 10, 2026 10 stories
- November 9, 2026 10 stories
- November 8, 2026 9 stories
- November 7, 2026 7 stories
- November 6, 2026 10 stories
- November 5, 2026 10 stories